Clinical Study Archives

Ivermectin Added to University of Minnesota COVID-19 Drug Trial

23/05/2021 No Comments

Leading the national trial is Dr. Carolyn Bramante, a U internal medicine specialist. Emphasizing the importance of this trial, she says, “Not everybody has access to the vaccine, whereas these medications are existing generics, already FDA-approved, that are available in most pharmacies around the world.” Dr. Bramante continued, “If we find evidence of benefit, [the drugs] could be used immediately anywhere.”

The International Ivermectin for Covid Conference: Recent findings from the Israeli trial of ivermectin versus placebo

25/04/2021 No Comments

The International Ivermectin for Covid Conference: Professor Eli Schwartz shares data and conclusions from his Israeli randomised controlled trial of ivermectin in mild to moderate covid-19.

The International Ivermectin for Covid Conference: Evidence from ongoing trials

24/04/2021 No Comments

Medical experts from around the world joined together to present the very latest real world research on repurposing ivermectin that has the ability to transform global efforts to fight the pandemic. Mr. Andrew Bryant provides an overview of ongoing trials and what they may add to the evidence base.

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

22/04/2021 No Comments

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Philippines Launches Major Ivermectin Clinical Trial to Investigate Efficacy During Unprecedented Spike in Cases

21/04/2021 No Comments

With a surge of SARS-CoV-2 infections and a vaccination drive totaling 1.3 million, the nation’s leadership faces an uphill battle when factoring in their total population of 108 million. Hence the growing interest in ivermectin and the request of hospitals for access to the drug for compassionate use.

NIH to Launch Massive ACTIV-6 Phase 3 Clinical Study Investigating Repurposed Drugs & Ivermectin May be on the List

20/04/2021 No Comments

NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.

The Chloroquine Wars Part X – A Discussion of the Insanity of the Chloroquine Wars

03/04/2021 No Comments

We discussed the Surgisphere debacle and other stories of “engineered research” during the pandemic, most of which I am currently preparing articles about.

The Chloroquine Wars Part VI – The Simple Logic of the Hydroxychloroquine Hypothesis

17/03/2021 No Comments

The Hydroxychloroquine Hypothesis: That there is some appropriate dosage of hydroxychloroquine, alone or in some combination with other medication, that successfully prevents some COVID-19 cases (PrEP/PEP) or treats some COVID-19 sufferers (Early/Late/Critical).
Remaining entirely unblemished after a year of trials and observations, the current evidence in favor of the Primary HCQ Hypothesis fully validates the HCQ Hypothesis. The logic is so simple that it almost feels like your livelihood would have to be on the line to deny it.

The Chloroquine Wars Part V – A Closer Look at RCTs Studying Hydroxychloroquine Efficacy

14/03/2021 No Comments

This is now one of the most well-studied treatments in the history of medicine, and the evidence is overwhelming. The chance that these results could occur at random is approximately 1 in 208 quadrillion. That is, p = 0.000000000000048. Having read a few thousand research papers, I have never before seen a p-value this low in the testing of medicine.

The Chloroquine Wars Part IV

07/03/2021 No Comments

Why then does the pharmaceutical industry and its promoters insist on conducting RCTs before something is accepted as true? RCTs take substantial amounts of time and significant resources to conduct. This creates a barrier to entry, especially for inexpensive solutions to medical problems. In other words, the myth that RCTs are some necessary “gold standard” is a deception that, along with regulatory agency, prevent any possibility for simpler and less expensive (less profitable) medical solutions to gain traction.

The Chloroquine Wars Part III

06/03/2021 No Comments

If the argument rests on “RCTs as the gold standard”, there is little doubt that the evidence dramatically favors using HCQ as a standard early stage therapeutic! But it is reasonable to assess the quality of all the evidence to reach beyond gold for the ultimate and supreme standards of scientific evidence. That too we plan to present in future articles.

The results of a meta-analysis of 187 studies treating COVID-19 successfully with hydroxychloroquine are statistically irrefutable.

05/01/2021 No Comments

HCQ is effective for COVID-19. The chance that an ineffective treatment generated results as positive as the 187 studies to date is 1 in 5 quadrillion (p = 0.00000000000000019).

Hydroxychloroquine Not Linked to Longer Heart Rhythm Intervals in Rheumatoid Arthritis or Lupus Patients

06/11/2020 No Comments

Of the whole study group (RA and SLE), 54% used hydroxychloroquine and 44% had QTc lengths of more than 440 milliseconds. They found that the adjusted QTc length among hydroxychloroquine users was comparable to those who did not use the drug.

C19study.com update: Now 118 international studies (71 peer reviewed) show positive hydroxychloroquine treatment outcomes

28/09/2020 No Comments

Source: C19Study A live and ongoing index of studies from around the world documenting the use of hydroxychloroquine in treatment at various stages of SARS-CoV-2 infection

C19 Study: 53 studies (31 peer reviewed) showing “very positive” results using HCQ as pre & post exposure prophylaxis & early treatment.

06/07/2020 No Comments

Source: c19 Study A live and ongoing index of study data from around the world documenting the use of hydroxychloroquine in treatment at various stages

National Cancer Instititute: List of Active Clinical Trials Using Hydroxychloroquine for Cancer

26/06/2020 No Comments

The clinical trials on this list are studying Hydroxychloroquine. All trials on the list are supported by NCI.

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France

19/06/2020 No Comments

Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies.

Indonesia Claims Five Drug Combos, including HCQ, Reduce Novel Coronavirus

12/06/2020 No Comments

Source: Jakarta Globe Researchers from Airlangga University, Government’s Covid-19 Task Force, and State Intelligence Agency (BIN) have claimed to have found combinations of medicine that effectively reduce the

80% dip in infection risk for Indian health staff on HCQ: Study

01/06/2020 No Comments

Source: Hindustan Times The results of the study are based on a case control study for which participants were randomly drawn from the countrywide Covid-19

50 Science References Supporting Hydroxychloroquine: Microbiology Professor at Universidade de São Paulo, Paola Zanotto

18/05/2020 No Comments

SOURCE: Covexit.com The esteemed professor Paolo Zanotto, from the University of Sao Paulo, has released a list of 50 scientific references supporting the use of

UW Medicine ramps up study of hydroxychloroquine and azithromycin for COVID-19 treatment

17/05/2020 No Comments

Source: GeekWire One of the treatments for COVID-19 — a combination of the antimalarial drug hydroxychloroquine and azithromycin, an antibiotic — is the subject of

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

15/05/2020 No Comments

Source: Springer Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments.

Tampa General Hospital workers in clinical trial using hydroxychloroquine as COVID-19 preventative

12/05/2020 No Comments

Source: Fox News TAMPA, Fla. – Frontline healthcare workers in Tampa are participating in a clinical trial to see if a drug being used to treat COVID-19 can actually

NYU: HCQ + azithromycin + zinc Vs. HCQ + azithromycin alone: outcomes in New York hospitalized COVID-19 patients

02/05/2020 No Comments

Source: MedRxiv This study provides the first in vivo evidence that zinc sulfate in combination with hydroxychloroquine may play a role in therapeutic management for

China study of 568 critically ill Covid-19 patients: Hydroxychloroquine treatment significantly associated with a decreased mortality, through attenuation of inflammatory cytokine storm.

01/05/2020 No Comments

Source: MedRxiv Abstract Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high mortality. The most urgent thing is to find

US clinical trials of hydroxychloroquine hit ‘warp speed,’ could show in weeks whether it works on coronavirus

16/04/2020 No Comments

Federal health regulators have fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape. Researchers at NYU Langone

Study to ask: Does antimalarial drug prevent COVID-19?

01/04/2020 No Comments

As with many infectious epidemics, household contacts, first responders, care givers, and medical personnel attending to persons with COVID-19 have a high risk of infection.

The Palmer Foundation

Tag: Clinical Study